SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-066311
Filing Date
2023-05-31
Accepted
2023-05-31 06:44:51
Documents
14
Period of Report
2023-05-31
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2317378d1_8k.htm   iXBRL 8-K 24065
2 EXHIBIT 99.1 tm2317378d1_ex99-1.htm EX-99.1 18393
6 GRAPHIC tm2317378d1_ex99-1img001.jpg GRAPHIC 6193
  Complete submission text file 0001104659-23-066311.txt   229674

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20230531.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20230531_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20230531_pre.xml EX-101.PRE 22597
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2317378d1_8k_htm.xml XML 3496
Mailing Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032
Business Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 23978892
SIC: 2834 Pharmaceutical Preparations